LONG TERM FOLLOW UP OF THE BATMO PROTOCOL (BEST-ANTIMICROBIAL-THERAPY-TMO) AND COMPARISON WITH HYSTORICAL DATA (SIE 2025) - Oct 27, 2025 - Abstract #C077; Pres time: Oct 21, 2025; 03:40 PM - 05:10 PM; Location: ROOM 4; "The main features of this protocol are the absence of fluoroquinolone prophylaxis during the neutropenic phase of allo-SCT, the administration of posaconazole in high-risk patients (pts), and letermovir in CMV-positive pts from day 0 to day +100. In particular, the lack of fluoroquinolone prophylaxis, despite being associated with an increased number of BSIs by day +30, does not impact NRM. Figure 1 and Table 1."
Clinical • Acute Graft versus Host Disease • Gastrointestinal Disorder • Graft versus Host Disease • Hematological Disorders • Immunology • Infectious Disease • Neutropenia • Pneumonia • Respiratory Diseases
|
|
L. Masina 1; S. Ferri 1; L. Signorini 2; F. Caccuri 3; S. Corbellini 3; S. Lorenzotti 4; M. Farina 1; E. Morello 1; V. Radici 1; G. Magliano 1; A. Caruso 3; D. Russo 1; E. Van Hauwermeiren 4; M. Malagola 1; D. Avenoso 1
|